Personalis Shares Rise 5% After VA Awards $13.5M Work Order.
PorAinvest
viernes, 22 de agosto de 2025, 7:04 am ET1 min de lectura
PSNL--
The task order, which takes effect on September 30, 2025, subject to the receipt of samples and the fulfillment of services, is a significant milestone for the cancer test maker. Personalis, known for its NeXT Personal cancer test, provides genome sequencing services as part of the VA MVP contract. This new order is expected to contribute to the company's ongoing revenue growth.
To date, Personalis has received nearly $225 million in task orders under its contracts with the VA MVP, which accounted for 9% of its topline in 2024 and 13% in 2023, respectively [1]. The company has been focusing on expanding its presence in the VA MVP program, which has shown strong potential for growth.
The latest order comes as the company continues to refine its strategic focus and expand its service offerings. Personalis reported its Q2 2025 earnings call, outlining a $70 million to $80 million revenue target for the year, along with a 59% sequential clinical test growth and a revised biopharma outlook [1].
In the current financial climate, investors are closely monitoring Personalis' performance, particularly its ability to secure large-scale contracts and execute on its strategic goals. The latest VA MVP task order is a positive indicator of the company's market position and its potential for future growth.
References:
[1] https://seekingalpha.com/news/4488258-personalis-stock-gains-va-work-order
Personalis shares rise 5% in premarket trading after receiving a $13.5M task order from the Department of Veterans Affairs. The order is under a contract with the VA and marks a significant milestone for the cancer test maker. The company's stock has increased in value following the announcement.
Personalis Inc. (NASDAQ: PSNL) saw its stock rise by approximately 5% in premarket trading on Friday following the announcement that it had received a new task order worth up to $13.5 million from the Department of Veterans Affairs (VA). The order is part of the VA Million Veteran Program (MVP), a large-scale population sequencing initiative [1].The task order, which takes effect on September 30, 2025, subject to the receipt of samples and the fulfillment of services, is a significant milestone for the cancer test maker. Personalis, known for its NeXT Personal cancer test, provides genome sequencing services as part of the VA MVP contract. This new order is expected to contribute to the company's ongoing revenue growth.
To date, Personalis has received nearly $225 million in task orders under its contracts with the VA MVP, which accounted for 9% of its topline in 2024 and 13% in 2023, respectively [1]. The company has been focusing on expanding its presence in the VA MVP program, which has shown strong potential for growth.
The latest order comes as the company continues to refine its strategic focus and expand its service offerings. Personalis reported its Q2 2025 earnings call, outlining a $70 million to $80 million revenue target for the year, along with a 59% sequential clinical test growth and a revised biopharma outlook [1].
In the current financial climate, investors are closely monitoring Personalis' performance, particularly its ability to secure large-scale contracts and execute on its strategic goals. The latest VA MVP task order is a positive indicator of the company's market position and its potential for future growth.
References:
[1] https://seekingalpha.com/news/4488258-personalis-stock-gains-va-work-order

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios